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Abstract
RNA viruses replicate with a template-copying fidelity, which lies close to an extinction
threshold. Increases of mutation rate by nucleotide analogues can drive viruses towards
extinction. This transition is the basis of an antiviral strategy termed lethal mutagenesis. We
have introduced a new diversity index, the rare haplotype load (RHL), to describe NS5B
(polymerase) mutant spectra of hepatitis C virus (HCV) populations passaged in absence or
presence of the mutagenic agents favipiravir or ribavirin. The increase in RHL is more promi-
nent in mutant spectra whose expansions were due to nucleotide analogues than to multiple
passages in absence of mutagens. Statistical tests for paired mutagenized versus non-muta-
genized samples with 14 diversity indices show that RHL provides consistently the highest
standardized effect of mutagenic treatment difference for ribavirin and favipiravir. The results
indicate that the enrichment of viral quasispecies in very low frequency minority genomes
can serve as a robust marker for lethal mutagenesis. The diagnostic value of RHL from deep
sequencing data is relevant to experimental studies on enhanced mutagenesis of viruses,
and to pharmacological evaluations of inhibitors suspected to have a mutagenic activity.
Introduction
The mutant spectra of RNA viruses are a reflection of their evolutionary history, as well as
important determinants of virus adaptability. Concerning control of viral diseases, mutant
spectrum dynamics is an obstacle for the efficacy of therapeutic interventions due to selection
of treatment-escape viral mutants. The antiviral agents to combat RNA viruses include those
directed to specific viral targets [direct-acting antiviral agents (DAAs)], and those that inhibit
cellular functions needed for the completion of the virus life cycle. The viral RNA-dependent
RNA polymerase (RdRp) is the target of several effective antiviral agents. Some of them, nota-
bly base or nucleoside analogues, are intracellularly converted into their active nucleotide
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counterparts. The discovery that ribavirin (1-β-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxa-
mide) is mutagenic for poliovirus [1] introduced a new perspective in the antiviral mechanism
of some nucleotide analogues. Three alternative ─not mutually exclusive─mechanisms of
anti-RdRp activity by nucleotide analogues have been described: RNA chain termination, inhi-
bition of RNA synthesis without chain termination, and inhibition associated with viral
genome mutagenesis.
Nucleotide analogue-induced mutagenesis is equivalent to a decrease of copying fidelity by
the viral RdRp. Quasispecies theory predicts a maximum amount of genetic information that
can be transmitted for a given average copying fidelity. This concept is mathematically formu-
lated in the form of an error threshold relationship. An increase in mutation rate drives the
population across the error threshold, into error catastrophe, equated with loss of inheritable
information [2, 3]. The error threshold applies to finite populations in variable fitness land-
scapes, and its position in a fidelity scale depends also on the degree of adaptation of the
mutant ensemble to the environment [3]. The error threshold concept has found experimental
support in studies on the negative effects of chemical mutagenesis on the survival of RNA
viruses ([4–8], among other studies). The convergence of theoretical and experimental results
opened the way to lethal mutagenesis as an antiviral strategy [9].
The licensed antiviral nucleoside analogues favipiravir (T-705; 6-fluoro-3-hydroxy-2-pirazi-
necarboxamide) and ribavirin are mutagenic for several RNA viruses. Ribavirin has been used
as antiviral agent for decades [10, 11], and only recently shown to be mutagenic for several
RNA viruses [1, 12, 13]. Favipiravir has been licensed as an anti- influenza agent in Japan having
potent antiviral activity against different influenza virus strains (types A, B and C) including
those resistant to neuraminidase and M2 inhibitors [14]. Favipiravir has also been effective to
inhibits the replication of other RNA viruses in vitro and in animal models, including flavi-,
noro- alpha-, bunya-, arena-, filovirus and other RNA virus for which no antiviral therapy is
currently available [reviewed in (15, 16)]. Favipiravir in converted intracellularly into the ribo-
furanosyl 5’-triphosphate metabolite (favipiravir-RTP) and in this form it can be recognized as
a pseudopurine by the RdRp [14, 17]. Its selective inhibition of RdRp implicates a wider anti-
viral spectrum with a limited cell damage compared with other mutagens such as Ribavirin.
Incorporation of favipiravir-RTP in the nascent viral RNA could result in lethal mutagene-
sis, as has been proposed for influenza virus [18], norovirus [7], hepatitis C virus (HCV) [19];
foot-and-mouth disease virus [20], West Nile virus [21], Dengue virus [22] and Ebola virus
[8]; coxsackievirus B3 [23]. It is not clear whether favipiravir acts as RNA chain terminator,
inhibitor, mutagen or by a combination of these mechanisms; its dominant mode of action
may depend on the virus-host system and concentration of the active form. In order to cause
lethal mutagenesis, favipiravir-RTP needs to be incorporated into the RNA without causing
immediate chain termination. It is possible that both lethal mutagenesis and chain termination
occur depending on the available concentration of favipiravir-RTP. It has been hypothesized
that incorporation of low levels of favipiravir-RTP could result in full-length extension of the
viral RNA, leading to lethal mutagenesis and lower infectivity [24].
The standard way to distinguish an RNA virus mutagen from a non-mutagenic inhibitor, is
that a mutagenic inhibitor promotes an increase of mutant spectrum diversity, and a decrease
of the virus specific infectivity (defined as the ratio of the number of infectious units to the
amount of viral RNA in the virus population) (reviewed in [25, 26]). The application of deep
sequencing to the analysis of viral populations has introduced several new diversity indices
that allow a more detailed description of mutant spectra [27–29]. Some diversity indices were
adopted from ecology, and are classified in three groups: incidence (based on the count of enti-
ties in a multiple alignment of haplotypes), abundance (that considers both, counts of entities
and their frequency), and functional (based on differences among the observed haplotypes)
RHL lethal mutagenesis
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[27]. The value of alternative diversity indices to diagnose the mechanism underlying the
expansion of mutant spectra is an unsolved issue.
We have adapted a HCV serial passage design to study the genetic and phenotypic diversifi-
cation of HCV in Huh-7.5 reporter cells in absence of cellular evolution [30–32]. The parental
(plasmid-derived) HCV population was passaged in absence or presence of ribavirin or favi-
piravir. Populations whose mutant spectrum was expanded in absence of drugs were also sub-
jected to mutagenesis. The design produced several HCV populations for comparative mutant
spectrum analyses. NS5B amplicons were analyzed to quantify mutant spectrum complexity.
We describe a new diversity index, the rare haplotype load (RHL), and show that its variation
outstands among that of other diversity indices to characterize mutant spectra in their transi-
tion into error catastrophe. RHL may help in the understanding of quasispecies dynamics, and
in the clarification of the mechanisms of action of antiviral agents.
Results
The rare haplotype load of hepatitis C virus populations
HCV RNA expressed from plasmid Jc1FLAG2(p7-nsGluc2A) (genotype 2a) [33] was trans-
fected into Huh-7 Lunet cells and amplified in Huh-7.5 cells to produce the initial virus popu-
lation HCV p0 [30]. HCV p0 was subjected to 200 serial passages in Huh-7.5 reporter cells in
the absence of any drug. The populations at passage 100 (HCV p100) and at passage 200 (HCV
p200) displayed increased replication in Huh-7.5 reported cells [31, 32]. HCV p0, HCV p100
and HCV p200 were further passaged either in the absence of any drug or in the presence of
favipiravir or ribavirin (Fig 1A). Infectious progeny levels were those expected from previous
quantifications of inhibition of HCV p0 by favipiravir [19] and ribavirin [34]; the sustained
HCV p100 and HCV p200 production in the presence of the drugs is expected from the fit-
ness-associated HCV resistance to antiviral agents [31, 32, 35] (Fig 1B).
Intracellular viral RNA was sequenced in MiSeq with 2x300 mode with v3 chemistry, and
fastq files were analyzed as previously described [27, 29] to obtain forward and reverse consen-
sus haplotypes with abundances not below 0.1%, median coverage 147,000 reads, interquartile
range (IQR) 75570–226100. The fasta files obtained for each sample were further subjected to
DSFT for diversity indices computation. The resulting median coverage was of 139200 with
IQR 71,480–210,600 reads.
We introduce the rare haplotype load (RHL) as a new diversity index which may be consid-
ered intermediate between incidence and abundance indices. In the context of this work we
define as rare those haplotypes with abundances below a given threshold (1%), and as load the
fraction of molecules in the quasispecies belonging to these haplotypes. Translating this con-
cept to next generation sequencing is not an easy task as we wish to take into account full reads
in the range of abundances below the instrument noise level. Our approach consisted in taking
all reads corresponding to haplotypes common to the forward and reverse strand with no pre-
vious abundance filtering and computing the RHL as the fraction of reads belonging to haplo-
types with abundances below 1%. We suppose that technical noise affects equally all samples in
the experiment and that the distinctive effect would be caused by the treatment. This index
was not submitted to any sample size correction.
Comparison of RHL with other diversity indices
A full set of diversity indices was computed for each sample: Hpl, number of haplotypes; Poly-
Sites, number of polymorphic sites; nMuts, number of mutations; Shannon, Shannon entropy;
GiniS, Gini-Simpson index; q1D, Hill number of order 1; q2D, Hill number of order 2; qInfD,
Hill number of order infinity; FAD, functional attribute diversity; Mf.e, mutation frequency by
RHL lethal mutagenesis
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entity; Pi.e, nucleotide diversity by entity; Pi, nucleotide diversity, and Mf, mutation frequency.
The correlation among all indices (including RHL) resulting from all samples in the experi-
mental design, shows a structure with three groups (Fig 2) G1: RHL, Hpl, FAD, nMuts and
PolySites; G2: Shannon, GiniS, q1D, q2D and qInfD; and G3: Mf.e, Pi.e, Mf and Pi. The three
indices more correlated to RHL are Hpl 0.895, FAD 0.854 and Shannon 0.826. RHL falls within
the group of incidence indices, but it results from the aggregation of abundances. Its high cor-
relation with Shannon and q1D denotes properties of abundance-based indices, while its high
correlation with FAD confers to RHL properties of functional incidence. These three proper-
ties were expected from the definition of RHL, and the correlations provide an empirical prove
of the computations adequacy.
Association tests
Table 1 summarizes the results of the association tests of each diversity index considered,
including RHL, to mutagenicity, for each drug (favipiravir and ribavirin) sorted by decreasing
order of standardized effect. No distinction has been made of amplicon or treatment length.
Hence the results represent averaging over the full NS5B region sequenced, and over the two
treatment lengths. The RHL is the index with the highest standardized effect among all in both
mutagenic treatments, with adjusted p-values of the order of 10−4. Top indices are also FAD,
Hpl, Shannon, nMuts, and PolySites. No significant association is found in neither treatment,
for Mf and Pi, both at the abundance and at the entity level. RHL is still the top indicator when
distinguishing among amplicons or treatment length, followed by FAD and Hpl.
Logistic regression
As a further step towards characterizing RHL as mutagenicity marker, samples were relabeled
as under mutagenicity (Mut) if treated with favipiravir or ribavirin, or not mutagenized (con-
trol) for passages in absence of drug. Each group includes the variability due to the factors
amplicon, drug, and treatment length. Then a univariate logistic regression was fit with each of
the diversity indices, including RHL (Figs 3 and S1). The regression to RHL resulted in the
best value of the Aikake Information content (AIC), the highest area under the ROC curve
(AUC), and the lowest leave-one out cross-validation (LOOCV) error rate to classification
(Table 2). According to the LOOCV error rate the predictive capacity of these indices follows
the order RHL, Hpl, PolySites, nMuts and FAD (S2 Fig).
When this analysis was performed separately for each treatment length, for 10 passes both
RHL, Shannon and q1D resulted in the lowest values of AIC and LOOCV, for 3 passes RHL,
FAD and Hpl resulted in the lowest values of AIC and LOOCV (S3 and S4 Figs). No multivari-
ate logistic regression model resulted better that RHL as a single predictor in the whole dataset.
These results prove that within the experimental design of this study RHL is the most sensi-
tive diversity index for predicting mutagenic effects, with independence of factors such as
amplicon, base line passage, drug, and treatment length.
In-silico study to test the robustness and unbiasedness of RHL
To study the robustness of RHL and its possible dependence on sample size, an in-silico study
on the full set of fasta files with no exclusion was performed. Robustness was evaluated by
Fig 1. Experimental design and infectious HCV progeny production in absence or presence of favipiravir or ribavirin. (A) Passage of HCV p0
in Huh-7.5 reporter cells to derive high fitness HCV p100 and HCV p200 populations. (B) Serial passages of HCV p0, HCV p100 and HCV p200 in
absence of drugs (No drug) or the presence of 400 μM favipiravir, or 100 μM ribavirin. (C) Infectious progeny production during 10 serial passages
in absence or presence of the drugs. Details on the infections are given in Materials and Methods.
https://doi.org/10.1371/journal.pone.0204877.g001
RHL lethal mutagenesis
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Fig 2. Correlation among diversity. (A) Plot illustrating the correlation between diversity indices in this study. The
correspondences between colors and correlation values is shown on the right bar. (B) Hierarchical clustering of
diversity indices computed with the square root of one minus the correlation matrix, as measure of dissimilarity.
https://doi.org/10.1371/journal.pone.0204877.g002
RHL lethal mutagenesis
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comparing RHL with the number of haplotypes, Hpl. According to the main statistics of the
distribution of median values obtained after 2000 simulation cycles on each fasta file, RHL is
on average five times less variable than Hpl, in terms of the coefficient of variation (CV) and of
interquartile dispersion (QD) (Table 3). The main statistics of the relative error of the median
value of RHL in the sample replicates indicate a median error of 0.04% with a maximum of
1.99%. This confirms that the observed value of RHL in a sample is unbiased and not influ-
enced by the sample size. No sample size correction was needed for RHL, contrary to most
diversity indices [27, 29]. Thus, RHL is far more stable and robust than Hpl and other diversity
indices to characterize a virus transition into error catastrophe with deep sequencing data.
Discussion
Comparison of diversity indices for complexity evaluation of mutant spectra of HCV popula-
tions has unveiled that RHL is a reliable index to diagnose mutant spectrum expansions associ-
ated with a mutagenic treatment. Previous studies with HCV quantified average 5.1-fold
(range 3.8–6.6) increases of mutation frequency following 200 serial large population passages
in Huh-7.5 cells, and 3.5-fold (range 1.6–5.6) increases as a result of up to 5 serial passages in
the presence of favipiravir or ribavirin [19, 32, 34]. Despite comparable or even larger muta-
tion frequency increases associated with multiple passages compared with mutagenic treat-
ments, RHL stood as a reliable, robust and unbiased marker for lethal mutagenesis. RHL is less
influenced by standard serial passages.
A salient informative role of RHL can be interpreted in the light of current evidence of the
molecular mechanisms that underlie the transition of RNA viruses towards an extinction
threshold. One event is suppression of viable genome replication by defective genomes that are
produced as a result of mutagenesis [36–38]. This is an extension to mutagenized populations
of the capacity of mutant spectra to suppress replication of high fitness cognate populations
[39]. Mutant-dependent interference was formulated as the lethal defection model of virus
extinction [40] that has as one of its consequences that during mutagenesis infectivity is lost
earlier that the capacity of viral RNA to replicate, thus leading to decrease of specific infectivity
Table 1. Wilcoxon signed rank test of paired samples, treatment vs control. Rows sorted in descending order of standardized effect. Estimate: median of treatment dif-
ference, SD: standard deviation, StdEffect: standardized effect (median divided by sd), p.value: Wilcoxon test p-value, adj.pv: multiple test adjusted p-value by the Bonfer-
roni method.
Ribavirin Favipiravir
Estimate SD StdEffect p.value adj.pv Estimate SD StdEffect p.value adj.pv
RHL 1,49E+01 5,09E+00 2,920 3,05E-05 4,27E-04 RHL 1,81E+01 3,86E+00 4,680 3,05E-05 4,27E-04
nMuts 2,05E+01 1,00E+01 2,040 3,58E-04 5,01E-03 Shannon 8,76E-01 4,22E-01 2,080 3,05E-05 4,27E-04
Hpl 2,25E+01 1,11E+01 2,020 3,61E-04 5,06E-03 FAD 1,74E+01 9,33E+00 1,860 6,10E-05 8,54E-04
PolySites 2,00E+01 9,92E+00 2,010 3,58E-04 5,01E-03 Hpl 2,75E+01 1,54E+01 1,790 5,45E-04 7,62E-03
FAD 1,21E+01 6,55E+00 1,850 3,05E-05 4,27E-04 GiniS 2,15E-01 1,39E-01 1,550 2,14E-04 2,99E-03
Shannon 6,99E-01 3,89E-01 1,800 3,05E-05 4,27E-04 q1D 5,18E+00 3,33E+00 1,550 3,05E-05 4,27E-04
GiniS 1,62E-01 1,27E-01 1,280 3,05E-04 4,27E-03 nMuts 2,60E+01 1,77E+01 1,470 1,59E-03 2,22E-02
q1D 4,04E+00 3,95E+00 1,020 3,05E-05 4,27E-04 PolySites 2,40E+01 1,71E+01 1,400 1,18E-03 1,65E-02
qInfD 7,74E-01 7,64E-01 1,010 5,80E-04 8,12E-03 q2D 1,56E+00 1,74E+00 0,901 3,05E-04 4,27E-03
q2D 1,58E+00 2,06E+00 0,766 3,05E-04 4,27E-03 qInfD 6,71E-01 9,05E-01 0,741 1,31E-03 1,84E-02
Mf.e 6,52E-04 1,55E-03 0,420 5,35E-02 7,49E-01 Pi 1,22E-03 2,04E-03 0,596 1,77E-02 2,47E-01
Pi 5,44E-04 1,34E-03 0,407 4,73E-02 6,62E-01 Pi.e 5,73E-04 1,40E-03 0,410 8,44E-02 1,00E+00
Mf 5,38E-04 1,37E-03 0,393 2,77E-02 3,88E-01 Mf 7,04E-04 2,32E-03 0,304 3,19E-02 4,46E-01
Pi.e 3,32E-04 1,17E-03 0,284 1,51E-01 1,00E+00 Mf.e 3,85E-04 1,72E-03 0,223 2,11E-01 1,00E+00
https://doi.org/10.1371/journal.pone.0204877.t001
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[19, 20, 34, 41, 42]. Examination of individual biological clones of viruses that remain viable
amidst a mutagenic treatment evidenced 200-fold reduction in infectivity, with 8-fold increase
in mutation frequency [43]. Therefore, the high RHL value in mutagenized populations is
likely to reflect a fundamental property of mutant spectra subjected to continuous mutagenesis
in which many low fitness genomes are generated. Such genomes, because of the continuous
input of new mutations, do not have the opportunity of fitness recovery thus replenishing a
low fitness sub-swarm captured by the RHL value. An increase in the proportion of minority
(low frequency) mutations has been observed in lethal mutagenesis experiments both in cell
culture [19, 20] and in vivo [8]. In mutant spectrum expansions that occur under basal muta-
tion rate, RHL is expected to be less abundant because no enhanced mutagenesis jeopardizes
opportunities for fitness gain, a tendency documented for RNA viruses when allowed unre-
stricted replication in a constant environment [31, 32, 44, 45].
Regarding diversity index adequacy to characterize lethal mutagenesis, RHL is followed by
the highly correlated incidence-based indices RHL, Hpl, nMuts, PolySites and FAD, the latter
probably because its entity level quality prevails under the conditions of our study. In contrast,
Fig 3. Logistic regression plot of mutagenicity over RHL. Red bars at the top depict the values of RHL for HCV
samples subject to mutagenesis. Blue bars at the bottom depict RHL values for control samples. Corresponding blue
and red dots on the fitted logistic curve show the predicted probability of mutagenesis for each sample, with a
predicted 50% probability at a RHL value of 37.5%. Area under the ROC curve 0.973. Only two samples under
mutagenic drug treatment and one control sample were mistakenly classified.
https://doi.org/10.1371/journal.pone.0204877.g003
RHL lethal mutagenesis
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Mf and Pi, despite being widely used in the description of mutant spectra, exhibit poor correla-
tion with mutagenesis treatment. We also examined by logistic regression the capacity of each
index to discriminate between a history of mutagenesis and non-mutagenesis accompanying a
mutant spectrum expansion. Sorting of indices by LOOCV error rate placed RHL on top, fol-
lowed by HpI, PolySites, nMuts, FAD and Shannon. No discriminating capacity is observed
for Mf, Pi, Mf.e and Pi.e, in agreement with the poor results of these indices in the association
tests. The performed logistic regression has aimed at a more complex scenario, recognizing a
mutagenic state independently of population history, where the signal could be blurred and
affected by different phases of quasispecies dynamics, either of expansion or contraction of its
mutant spectrum.
It could be anticipated that multivariate models such as logistic PCLR and PLSLR might
describe the mutagenic effects more accurately than individual indices by adding the contrib-
uted predictive capacity of different indices despite its high correlation, in the sense that they
could have a higher incidence with samples under mutagenic effect. But no logistic multivari-
ate model beats RHL as a single predictor.
The information we seek to be captured with RHL lies below technical noise. Our approach
has consisted in supposing that technical noise affects equally all samples in the experiment
Table 2. Results of the logistic regressions. Dev: residual deviance. AIC: Aikake Information Content. Sensit: Sensitivity. Specif: Specificity. AUC: area under the ROC
curve. Err: classification error rate. LOOCV: Leave-one-out cross-validation error rate.
Index Dev AIC Sensit Specif AUC Err TenFoldCV LOOCV
RHL 19,6 23,6 0,933 0,958 0,973 0,056 0,057 0,055
Hpl 24,2 28,2 0,867 0,917 0,968 0,111 0,123 0,111
PolySites 44,2 48,2 0,800 0,875 0,899 0,167 0,176 0,165
nMuts 45,3 49,3 0,800 0,875 0,897 0,167 0,176 0,172
FAD 36,5 40,5 0,867 0,792 0,928 0,167 0,182 0,181
Shannon 49,7 53,7 0,833 0,750 0,863 0,204 0,208 0,204
q1D 50,4 54,4 0,800 0,792 0,863 0,204 0,215 0,221
q2D 62,5 66,5 0,633 0,833 0,738 0,278 0,290 0,278
qInfD 62,8 66,8 0,633 0,833 0,724 0,278 0,298 0,312
GiniS 62,4 66,4 0,767 0,542 0,738 0,333 0,345 0,367
Pi.e 74,1 78,1 1,000 0,000 0,557 0,444 0,485 0,465
Pi 72,3 76,3 0,700 0,292 0,597 0,482 0,539 0,516
Mf 71,4 75,4 0,633 0,417 0,589 0,463 0,520 0,529
Mf.e 73,4 77,4 0,933 0,208 0,562 0,389 0,494 0,571
https://doi.org/10.1371/journal.pone.0204877.t002
Table 3. Results of the in-silico study to characterize the biasedness and robustness of RHL with respect to Hpla. The table provides a summary of distributional val-
ues for the % error with respect to the true value of RHL (top row); the coefficient of variation (CV) observed for RHL and Hpl, rows second and third; the ratio of both
CVs in row fourth; the interquartile deviation (QD) observed for RHL and Hpl, rows fifth and sixth; and the ratio of both QDs in the last row.
Min. Q1 Median Mean Q3 Max.
RHL.err % 0,00 0,02 0,04 0,25 0,32 1,99
RHL.cv 0,0048 0,0077 0,0098 0,0109 0,0134 0,0211
Hpl.cv 0,0279 0,0399 0,0443 0,0505 0,0548 0,1086
CV.ratio 2,1 3,2 4,7 5,3 6,9 13,1
RHL.qd 0,0057 0,0097 0,0120 0,0147 0,0184 0,0378
Hpl.qd 0,0000 0,0488 0,0606 0,0637 0,0741 0,1538
QD.ratio 0,0 2,9 5,1 5,2 7,0 13,7
https://doi.org/10.1371/journal.pone.0204877.t003
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and that the distinctive effect would be caused by mutagenesis; that level will include both
authentic rare haplotypes and those that are introduced by technical noise.
Deep sequencing has become an important tool to analyze viral populations subjected to
mutagenic treatments [8, 22, 46]. The ranking of diversity indices to best characterize mutant
spectra subjected to lethal mutagenesis is relevant to a growing body of fundamental and
applied studies in virology and microbial genetics in general. Multiple high and low fidelity
RNA virus mutants have been characterized [47], and how such mutants modify diversity indi-
ces is an open question that may shed light on the biological consequences of altered polymer-
ase fidelity. Also, a large RHL questions the meaning of lethality of mutations in viral and
microbial populations [41, 48–51]. Specifically, it is not clear whether the genomes that con-
tribute to the RHL are slow replicators that can participate in evolutionary events, or are dead-
end products transiently kept in viral populations by complementation [41, 52]. Ranking of
diversity indices may provide also relevant information on the adaptative dynamics under
enhanced mutagenesis [53], or the action of mutagenic agents on plant viruses [54]. From the
perspective of pharmacology, RHL offers the means to distinguish whether base or nucleoside
analogues that display antiviral activities affect viral RNA replication by direct inhibition of
polymerase function or by enhanced mutagenesis, thus contributing to clarify uncertainties of
drug action. The mechanism of activity of nucleotide analogues has consequences for the types
of drug combinations that used together or sequentially can exert a more suppressive antiviral
effect [55–58]. Studies with additional viruses, fidelity mutants, and nucleotide analogues are
needed to provide a clearer picture of the relevance of different diversity indices to characterize
mutant spectra with alternative evolutionary histories. Cellular heterogeneity in important
clinical disorders such as cancer parallels the population dynamics and the collective behavior
of RNA viruses. Evaluation of a possible applicability of RHL determination as a marker in the
mutagenic spectra generated during different cellular tumogeneric processes could also be
considered. The present study, however, points towards RHL as a valuable marker for lethal
mutagenesis of virus, and emphasizes that the choice of diversity indices to describe mutant
spectra is not trivial.
Materials and methods
Cells, viruses, infections, and drugs
Huh-7.5 and Huh-7.5 reporter human hepatoma cell lines were grown in Dulbecco’s modified
Eagle’s medium, and controlled as previously described [30, 32, 59, 60]. HCV p0 is the parental
viral population obtained by electroporation into Huh-7.5-Lunet cells of a transcript of plas-
mid Jc1FLAG2(p7-nsGluc2A) (a chimera of J6 and JFH-1, genotype 2a) [33], and amplified in
Huh-7.5 cells [30]. HCV p100 and HCV p200 resulted from population HCV p0 passaged 100
and 200 times, respectively, in Huh-7.5 reporter cells, as described [32]. Fitness of HCV p100
and HCV p200 relative to HCV p0 was measured in different growth-competition experiments
between virus pairs. In initial determinations at a total MOI of 0.03 TCID50/cell, HCV p100 fit-
ness was 2.2±0.4 that of HCV p0 [31]. Subsequent determinations gave 1.28±0.34 at a MOI of
0.03 TCID50/cell, and 1.10±0.02 TCID50/cell at a MOI of 1 TCID50/cell; the corresponding val-
ues for HCV p200 relative to HCV p0 were 1.33±0.46 and 1.17±0.02, respectively [32]. Infec-
tious HCV was titrated as previously described [32]: serially diluted samples were applied to
Huh-7.5 cells in 96-well plates (6,400 cells/well seeded 16 h earlier), and three days post-infec-
tion, cells were washed with PBS, fixed with ice-cold methanol, and stained to detect anti-
NS5A monoclonal antibody 9E10 [61]. Titrations were performed in triplicate, and titers
expressed as TCID50/ml. Favipiravir (T-705) (Atomax Chemicals Co. Ltd) and ribavirin
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(Sigma) were prepared and used as previously described [19, 34, 35]. Their concentrations
were chosen to produce comparable inhibition of HCV p0 progeny production.
RNA extraction, cDNA amplification and deep sequencing
Total intracellular viral RNA was extracted from infected cells using the Qiagen RNeasy kit
(Qiagen, Valencia, CA, USA), according to the manufacturer’s instructions. RT-PCR was car-
ried out using AccuScript (Agilent Technologies), with specific oligonucleotide primers (S1
Table) The amplicons covered the following genomic regions: A1, spanning genomic residues
7626 to 7962; A2, residues 7941 to 8257; and A3, residues 8229 to 8653. Negative controls with-
out template RNA were included in parallel to ascertain the absence of cross-contamination by
template nucleic acids. PCR products were purified (QIAquick Gel Extraction kit), quantified
(Pico Green assay), and analyzed for quality (Bioanalyzer) prior to Illumina MiSeq
sequencing.
Experimental design
The experiment is described schematically in Fig 1A and 1B, as described above. Four factors
have been considered. (i) Amplicon, with three levels A1, A2 and A3. Different regions in the
ORF are submitted to different functional restrictions. (ii) Base-line passage, with analyses at
passes 0, 100 and 200, where starts quasispecies evolution in absence or presence of treatment.
(iii) Treatment, with three levels: no drug, favipiravir and ribavirin. (iv) Treatment passages,
with analyses at passes 3 and 10. (Fig 1).
Bioinformatics and statistics
All computations were done in the R environment and language (Team R 2017).
Fastq data treatment
The fastq files obtained from the MiSeq were subjected to the following treatment. A haplo-
type-centric data analysis pipeline was developed on targeted samples by amplicons following
described procedures [62, 63] adapted to the Illumina MiSeq platform in a paired-end 2x300
mode. It involved the following steps:
• Quality control of fastq files by inspecting profiles of per-site quality, read length and general
instrument parameters of quality.
• In paired-end experiments overlap paired reads by FLASh [64] imposing a minimum of
20bp overlapped with a maximum of 10% mismatches.
• Quality profiles of FLASh reads.
• Demultiplex reads by identifying oligonucleotide sequences within windows of expected
positions in the sequenced reads.
◦ By MID (10bp oligonucleotide) distinguishing samples from different patients/origins,
only one mismatch is allowed.
◦ By specific primer (20-30bp oligonucleotides) distinguishing different regions in the
genome, and the two strands, up to three mismatches are allowed.
◦ Trim MIDs and primers.
◦ As a result, obtain a fasta file by each combination of MID, primer and strand in the run,
where the reads were collapsed to haplotypes with corresponding observed frequencies.
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• Align haplotypes in each fasta file to the wild type reference sequence or the master sequence
in the file (most abundant haplotype) and quality filter.
◦ Discard haplotypes not covering the full amplicon.
◦ Discard haplotypes with more than two indeterminations, three gaps or more than 30%
differences with respect to the reference.
◦ Repair accepted indeterminations and gaps as per the reference sequence.
• Intersect haplotypes in both strands with a minimum abundance of 0.1%
◦ Select haplotypes in both strands with abundances not below 0.1%
◦ Discard haplotypes unique to one strand.
◦ Take coverage of haplotypes passing the filter as the sum of reads in both strands.
• The final haplotypes are called consensus haplotypes, and are the basis of the downstream
analysis, except for the rare haplotypes load. Final yield 15–25% with respect to raw reads.
The pipeline consists in a set of R [65] scripts using objects and functions in packages Bio-
strings [66], ShortRead [67], and ape [68].
Rare haplotypes load (RHL)
It is computed as the fraction of reads in the sample belonging to haplotypes common to the
forward and reverse strands with abundance below a given threshold. In the present work 1%,
0.1% and 0.01% have been studied as thresholds, finally taking 1% as the most informative and
reliable.
Down sampling and fringe trimming (DSFT)
To compensate for possible biases in diversity indices due to differences in sample size [27, 29]
we used down-sampling followed by fringe trimming, which consists in the following steps: (i)
start with fasta files collecting the set of consensus haplotypes with abundance not below 0.1%;
(ii) compute the total number of reads in each fasta file in the analysis, and take the minimum
as the reference size; (iii) re-size the read number of each haplotype in each fasta file to the ref-
erence size; (iv) filter out all haplotypes below 0.2% with 95% confidence. These are the haplo-
types and frequencies used in the computation of all diversity indices, except for RHL.
Association tests
Association tests of all indices with mutagenicity were computed by the non-parametric Wil-
coxon signed rank test for paired samples, comparing the diversity values of the mutagenic
treatment samples versus the paired control samples, and correcting the p-values for multi-test
by the Bonferroni method; we did not distinguish among amplicons. Function wilcox.test with
alternate as greater and in paired mode, and p.adjust in package ‘stats’ were used in the com-
putations. Rather than declaring association at any p-value threshold, the models were ranked
according to descending order of the standardized effect. The most associated index is consid-
ered to be that with the highest effect and still with a low p-value.
Logistic regression
Logistic regression was used to fit a predictive model of mutagenic activity regardless of the
other factors in the design. Computations were performed by function glm in package ‘stats’.
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To assess the predictive error rate of a fitted model, a sample was considered as under muta-
genic effects if the fitted probability was above 0.5. The parameters used in the assessment
were: residual deviance, Aikake Information Content (AIC), sensitivity, specificity, area under
the ROC curve, and classification error rate. To minimize bias due to overfitting, the cross-val-
idation error rate under 11-fold cross-validation and under leave-one-out cross validation
(LOOCV) was used. The models were sorted by increasing order of LOOCV. Function cv.glm
in package ‘boot’ was used for the computation of CV error rates [69].
In silico study
An in-silico analysis was performed to assess the robustness of RHL when compared with Hpl.
To this aim, a fasta file of a sample with all haplotypes common to the forward and reverse
strands with no previous abundance filter was used to sample and compute its RHL. Then the
following steps were repeated 2000 times: (i) take a sample of 40,000 reads from the popula-
tion; (ii) compute the RHL of this sample, (iii) filter out all haplotypes with abundance below
0.1% and not common to both strands; (iv) DSFT to 20,000 reads with haplotypes not below
0.2% with 95% confidence; (v) count Hpl. In each cycle the number of final reads, haplotypes,
and RHL was computed and registered. With the set of 2000 values computed for each fasta
file, the mean, median, coefficient of variation (CV), and interquartile dispersion coefficient
(QD) were determined. A robust index is that showing the lowest CV and QD.
Free available R package. An R package collecting all important functions, the package
manual, and tutorial vignettes are freely available from GitHub (https://github.com/
VHIRHepatiques/QSutils).
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